Oxytocin CD Pharma: Uses, Dosage & Side Effects
Intranasal oxytocin 6.7 micrograms per dose — used to support the milk ejection reflex during breastfeeding.
Oxytocin CD Pharma is a nasal spray containing the peptide hormone oxytocin at a strength of 6.7 micrograms per metered dose. It is prescribed to breastfeeding mothers whose natural let-down reflex is delayed, weak or inconsistent, typically in the first days and weeks after giving birth. A single puff in one nostril a few minutes before a feed or a pumping session helps the body release milk from the alveoli into the ducts so the baby can obtain milk more easily. Because oxytocin is an established physiological hormone used in low intranasal doses, Oxytocin CD Pharma is well tolerated when used as directed, although it is prescription-only and should be used under medical supervision. This guide summarises the evidence-based uses, correct dosing, warnings, drug interactions, side effects and storage of Oxytocin CD Pharma in line with international lactation and obstetrics guidelines.
Key Takeaways
- Targeted lactation support: Oxytocin CD Pharma is used short-term to trigger the milk ejection reflex when breastfeeding or expressing milk.
- Acts within minutes: A single intranasal dose typically produces let-down within 2–5 minutes; administer just before a feed or pumping session.
- Not for pregnancy: The medicine must not be used during pregnancy because it can stimulate uterine contractions.
- Low-dose, locally tolerated: The 6.7 mcg nasal dose is far lower than obstetric infusion doses, so serious systemic effects are rare.
- Adjunct, not a substitute: It complements — rather than replaces — correct latch, frequent feeding, skin-to-skin contact and lactation consultant support.
What Is Oxytocin CD Pharma and What Is It Used For?
Quick answer: Oxytocin CD Pharma is a prescription nasal spray that delivers 6.7 micrograms of the natural hormone oxytocin per puff. It is used to stimulate the milk ejection (let-down) reflex in breastfeeding mothers when that reflex is impaired or insufficient.
Oxytocin CD Pharma belongs to a class of medicines called posterior pituitary hormones. Its active ingredient, oxytocin, is a nine–amino-acid peptide that is produced naturally by the hypothalamus and released from the posterior pituitary gland in response to physiological stimuli such as labour and suckling. In the context of breastfeeding, oxytocin binds to receptors on the myoepithelial cells surrounding the milk-producing alveoli in the breast. When those receptors are activated, the alveoli contract and milk is propelled down the ducts toward the nipple — the familiar sensation of "let-down."
When the let-down reflex is unreliable — for example after a caesarean section, following a difficult delivery, when the mother is under significant stress, when mother and baby have been separated, or when expressing milk with a pump — the body may not release oxytocin in sufficient amounts. This can make feeds longer, milk transfer less efficient, and pumping sessions frustrating. Oxytocin CD Pharma provides a small exogenous dose of the same hormone the body normally produces, delivered through the nasal mucosa directly into the bloodstream, where it mimics the physiological surge required to trigger milk ejection.
The main clinical indication is support of the milk ejection reflex in breastfeeding women during the early post-partum period. It is particularly useful for women who have mechanical difficulties starting a let-down, for mothers of premature babies who rely heavily on pumping, and for mothers who find expressing at work or away from their baby difficult because of a slow response to the pump. The medicine is intended as a short-term aid alongside non-pharmacological measures rather than as a long-term treatment.
It is important to distinguish Oxytocin CD Pharma from obstetric oxytocin products. Oxytocin injection or infusion used in hospitals for labour induction, augmentation of contractions, or prevention of postpartum haemorrhage delivers much higher systemic doses and is administered under continuous medical monitoring. The intranasal product is a low-dose, targeted formulation designed specifically for the much smaller hormonal surge needed to trigger milk ejection.
Oxytocin CD Pharma does not directly increase milk production. Milk supply is primarily regulated by prolactin and by frequent and effective removal of milk from the breast. What oxytocin does is make the milk that is already stored in the alveoli more available to the baby or pump. Many women perceive this as "having more milk," but the underlying mechanism is improved delivery, not increased synthesis.
What Should You Know Before Taking Oxytocin CD Pharma?
Quick answer: Oxytocin CD Pharma must not be used during pregnancy or by anyone with known hypersensitivity to oxytocin. Caution is needed in cardiovascular disease, hypertension, severe nasal inflammation and after recent nose surgery. Always follow the prescriber's advice.
Before your first dose, discuss your full medical history with your doctor, midwife or lactation consultant, including any chronic conditions, recent surgeries, current medicines, nutritional supplements, and any previous reactions to medicines. Let the prescriber know if you are planning another pregnancy, if you have a history of pre-eclampsia or cardiovascular disease, or if you frequently use decongestant or steroid nasal sprays, as any of these may influence whether Oxytocin CD Pharma is appropriate for you.
Contraindications
Oxytocin CD Pharma must not be used in the following situations:
- Known hypersensitivity to oxytocin or to any of the listed excipients (such as chlorobutanol, sorbitol or citrate buffer).
- Pregnancy. Because oxytocin stimulates uterine contractions, its use during pregnancy can trigger premature labour or miscarriage.
- Situations where uterine contractions are dangerous, for example in the presence of unexplained vaginal bleeding, severe cardiovascular disease or conditions where vasopressor/oxytocic agents are medically contraindicated.
- Severe nasal disease that would prevent reliable absorption of the spray or create a risk of systemic overexposure — this is a clinical judgment made by the prescriber.
Warnings and Precautions
Oxytocin is generally well tolerated at the low intranasal dose of 6.7 micrograms, but several precautions are important:
- Cardiovascular disease and hypertension. Although systemic effects are small at the nasal dose, oxytocin can affect blood pressure and heart rate in susceptible individuals. Monitor for palpitations, chest discomfort or marked changes in blood pressure.
- History of water retention or hyponatraemia. Oxytocin has mild antidiuretic activity. The tiny nasal doses used for let-down rarely cause fluid retention, but women with heart failure, kidney disease, or those receiving large volumes of IV fluids should use the medicine cautiously.
- Nasal mucosa integrity. Inflammation, heavy congestion, recent nose surgery, or frequent use of decongestant sprays can reduce absorption and efficacy. If you have a severe cold, the effect may be diminished.
- Unusual uterine cramping. Light uterine cramping (particularly in the first days after delivery during breastfeeding) is physiological. Unusually strong or persistent cramping after using the spray should be reported to a healthcare professional.
- Do not share the bottle with another person. The applicator is personal and may carry nasal flora between users.
Pregnancy and Breastfeeding
Oxytocin CD Pharma is intended specifically for breastfeeding women after delivery. It is not indicated, licensed or safe during pregnancy because oxytocin is a uterotonic and can initiate or intensify contractions that may harm the pregnancy. If you discover you are pregnant while still using Oxytocin CD Pharma, stop the spray and contact your doctor or midwife promptly.
During breastfeeding, the benefit-risk balance of Oxytocin CD Pharma is generally favourable. Oxytocin is a naturally occurring hormone produced during every breastfeed, and the small exogenous dose delivered intranasally replicates rather than overwhelms the physiological surge. Because oxytocin is a peptide, any minimal amount that might transfer into breast milk would be rapidly broken down by proteolytic enzymes in the infant's stomach and would not be absorbed intact. International references such as the US National Library of Medicine's LactMed database and the Academy of Breastfeeding Medicine (ABM) consider intranasal oxytocin compatible with continued breastfeeding when used as prescribed.
If a new pregnancy is confirmed or strongly suspected, treatment should be discontinued immediately and the prescriber notified.
Fertility and Contraception
Oxytocin CD Pharma is not known to impair fertility. It does not provide contraception. Breastfeeding itself can reduce fertility for some women (the lactational amenorrhoea method), but this is not reliable for everyone, and a reliable contraceptive method should be discussed with the healthcare provider if a further pregnancy is to be avoided.
How Does Oxytocin CD Pharma Interact with Other Drugs?
Quick answer: Clinically important interactions at the intranasal dose are limited, but caution is needed with prostaglandins, vasoconstrictor decongestants and certain nasal products that may alter absorption or amplify uterotonic effects.
The intranasal dose of 6.7 micrograms is small compared with obstetric doses, so systemic drug–drug interactions are modest. The main interactions relate either to local absorption (what happens in the nose) or to pharmacological additivity with medicines that also stimulate uterine contraction or blood vessel constriction. Tell your prescriber and pharmacist about all prescribed medicines, over-the-counter products, herbal remedies, nasal sprays and dietary supplements you are using.
Major Interactions
| Interacting substance | Type of interaction | Clinical advice |
|---|---|---|
| Prostaglandins (e.g. dinoprostone, misoprostol) | Additive uterotonic effect | Avoid concurrent use. Risk of excessive uterine contractions. |
| Ergot alkaloids (e.g. methylergometrine) | Additive uterotonic/vasoconstrictor effect | Do not combine unless supervised by an obstetric specialist. |
| Sympathomimetic decongestants (oxymetazoline, xylometazoline, phenylephrine) | Reduced nasal absorption due to vasoconstriction | Separate doses by at least 30–60 minutes; avoid chronic use. |
| Large intravenous fluid loads | Increases theoretical risk of water retention / hyponatraemia | Relevant mainly in hospitalised patients; unlikely at home. |
Minor Interactions
| Interacting substance | Type of interaction | Clinical advice |
|---|---|---|
| Nasal corticosteroids (e.g. mometasone, fluticasone) | Possible change in nasal mucosal absorption | Generally compatible; separate by a few minutes. |
| Antihistamine nasal sprays | Minor local interaction | Space by 10–15 minutes if used together. |
| Antihypertensive medicines | Theoretical additive effect on blood pressure | Monitor if pre-existing hypertension is treated. |
| Alcohol | May suppress let-down reflex independently | Avoid alcohol around breastfeeding times. |
Smoking, stress and significant sleep deprivation are not strictly "drug interactions" but are well documented to reduce the endogenous let-down reflex and can blunt the effect of Oxytocin CD Pharma. Addressing these factors generally improves the response to the medicine.
What Is the Correct Dosage of Oxytocin CD Pharma?
Quick answer: The usual adult dose is one puff (6.7 micrograms) in one nostril 2–5 minutes before breastfeeding or pumping. Use as needed around feeds, not continuously. Children do not use this medicine. Always follow the dose your prescriber has chosen for you.
Dosage must always follow the instructions given by your prescriber and the package leaflet supplied by the pharmacy. The information below describes the typical prescribing pattern for intranasal oxytocin 6.7 micrograms/dose for breastfeeding support and is not a substitute for individual medical advice.
Adults (Breastfeeding Women)
Standard dose
One puff (6.7 micrograms) into one nostril, 2–5 minutes before each breastfeed or pumping session. If a satisfactory let-down is not achieved, a second puff in the other nostril can be given after 5 minutes. Alternate nostrils between sessions to minimise local irritation.
How to use the spray
- Blow your nose gently to clear both nostrils.
- Remove the protective cap and hold the bottle upright.
- On first use or after more than a week without use, prime the pump by pressing 2–3 times into a tissue until a fine mist appears.
- Tilt your head slightly forward. Close one nostril with a finger, place the nozzle just inside the open nostril, and breathe in gently while pressing firmly down once.
- Wait 2–5 minutes before attaching the baby or starting the pump.
- Wipe the nozzle and replace the cap.
Treatment duration
Oxytocin CD Pharma is typically used for a few days up to a few weeks while the natural let-down reflex becomes reliable. Long-term continuous use is not recommended. Re-evaluate the need for treatment with your prescriber or lactation consultant regularly.
Children
Oxytocin CD Pharma is not intended for paediatric use. The medicine is prescribed only to breastfeeding mothers. Accidental exposure of a child to the nasal spray should be reported to a poisons information service, although the dose involved in a single puff is very small.
Elderly
Because this medicine is used to support breastfeeding after recent childbirth, use in older women is not clinically relevant. There are no elderly-specific dose adjustments.
Missed Dose
Oxytocin CD Pharma is used on demand immediately before a feed or pumping session, not on a fixed schedule. There is therefore no "missed dose" in the traditional sense. If you forget to use the spray before a feed, simply use it the next time and do not double the next dose to "catch up." Do not use more than the maximum daily number of puffs recommended by your prescriber.
Overdose
Inadvertently using several extra puffs is unlikely to cause serious harm at the 6.7 microgram dose, but repeated overdosing can increase the risk of uterine cramping, headache, nausea, flushing or — very rarely — water retention (hyponatraemia). If a large amount of the spray has been accidentally ingested or inhaled, or if you experience severe cramping, confusion, seizures or chest pain, seek urgent medical attention and take the package with you. In emergencies, call your local emergency number (see Emergency Numbers).
What Are the Side Effects of Oxytocin CD Pharma?
Quick answer: Most women experience no side effects or only mild, short-lived local effects such as nasal irritation, sneezing, or mild uterine cramping during feeds. Serious reactions are rare at the low intranasal dose.
Side effects are classified by frequency following the standard international convention: very common (more than 1 in 10 users), common (between 1 in 100 and 1 in 10), uncommon (between 1 in 1 000 and 1 in 100), rare (between 1 in 10 000 and 1 in 1 000) and very rare (fewer than 1 in 10 000). Individual response varies; most women tolerate Oxytocin CD Pharma well. Report any persistent or worrying symptom to your prescriber or pharmacist. Suspected adverse drug reactions can also be reported to national pharmacovigilance authorities (for example the EMA, MHRA, FDA or local equivalent).
Very Common
- Mild uterine cramping ("after-pains") during breastfeeding — largely a physiological consequence of let-down itself.
Common
- Local nasal irritation, burning sensation or dryness in the nose.
- Sneezing shortly after administration.
- Runny nose (rhinorrhoea).
- Mild, transient headache.
- Nausea.
Uncommon
- Flushing or a warm sensation in the face.
- Mild changes in heart rate or palpitations.
- Minor increase or decrease in blood pressure.
- Tingling sensation in the nipple or breast.
- Nosebleed (epistaxis).
Rare / Very Rare
- Allergic reaction — rash, itching, swelling of the face, lips or tongue; requires immediate medical attention.
- Difficulty breathing or wheeze (possible hypersensitivity).
- Hyponatraemia or water retention — more relevant in hospitalised patients receiving high-dose oxytocin infusions, very rare at intranasal doses.
- Seizures (extremely rare, in association with severe hyponatraemia).
- Persistent or severe nasal mucosal damage with prolonged misuse.
Seek immediate medical attention if you develop signs of a serious allergic reaction (anaphylaxis), severe chest pain, confusion, seizures, or unusually strong and prolonged uterine contractions after using the spray. Mild local nasal irritation that persists for more than a few days or any unexpected symptom should be reviewed by your prescriber, who may advise switching nostrils, reducing frequency, or stopping the medicine.
How Should You Store Oxytocin CD Pharma?
Quick answer: Store unopened bottles in the refrigerator at 2–8°C. Once opened, keep at or below 25°C and use within about 4 weeks, or as stated on the package. Do not freeze. Keep out of sight and reach of children.
Correct storage preserves the potency of the peptide hormone and ensures a reliable dose at every puff. Oxytocin is sensitive to heat and light, so improper storage can reduce its effectiveness.
- Before opening: Store in a refrigerator at 2–8°C. Keep the bottle in the original carton to protect it from light.
- After opening: Store at or below 25°C. Use within the in-use period stated in the package leaflet (typically 4 weeks). Write the opening date on the label to help you keep track.
- Do not freeze. Freezing can denature the peptide and damage the spray mechanism.
- Do not use after the expiry date printed on the carton and bottle. The expiry date refers to the last day of that month.
- Keep out of sight and reach of children. Although the dose per puff is low, accidental exposure should be avoided.
- Transport and travel: For journeys shorter than the in-use period, the opened bottle can be carried at ambient temperature below 25°C. For longer trips, plan for refrigerated storage on arrival.
- Disposal: Do not throw away unused medicines via wastewater or household waste. Return any unused medicine to a pharmacy for safe disposal, following local environmental guidelines.
What Does Oxytocin CD Pharma Contain?
Quick answer: Each metered dose contains 6.7 micrograms of synthetic oxytocin. The inactive ingredients typically include chlorobutanol hemihydrate (preservative), sorbitol, citric acid, sodium citrate and purified water for injection.
The exact composition is provided in the package leaflet that accompanies each bottle. In general, intranasal oxytocin 6.7 microgram/dose sprays contain:
Active ingredient
- Oxytocin — 6.7 micrograms per metered dose (equivalent to approximately 4 international units per millilitre, depending on formulation).
Inactive ingredients (typical)
- Chlorobutanol hemihydrate — preservative to maintain sterility after opening.
- Sorbitol — tonicity agent.
- Citric acid monohydrate and sodium citrate — buffering agents to stabilise the pH of the solution.
- Water for injections — solvent.
Patients with known hypersensitivity or intolerance to any of these excipients should inform their prescriber before starting treatment. If the package leaflet in your box lists different excipients, those are the definitive ingredients for your specific batch.
Appearance and packaging
Oxytocin CD Pharma is supplied as a clear, colourless to slightly yellowish aqueous solution in a multi-dose nasal spray bottle equipped with a metering pump. Each bottle typically delivers a defined number of actuations. The specific pack size, number of actuations per bottle, and exact fill volume are indicated on the carton.
Frequently Asked Questions
How quickly does Oxytocin CD Pharma nasal spray work?
Intranasal oxytocin is absorbed through the nasal mucosa and reaches peak plasma concentrations within approximately 2–7 minutes. Most women experience the milk ejection (let-down) reflex within 2–5 minutes of administration, which is why the spray is used just before a feed or pumping session.
Will Oxytocin CD Pharma increase how much milk I make?
Not directly. Milk supply is driven mainly by prolactin and by how frequently and effectively milk is removed from the breast. Oxytocin CD Pharma helps the milk already produced move from the alveoli to the baby (or pump) more efficiently. Better let-down often leads to more effective drainage, which can support supply over time, but the spray is not a substitute for frequent, effective feeding.
Is it safe to use the spray between feeds?
The medicine is intended for use immediately before a feed or pumping session. Continuous use between feeds is not recommended because the hormonal effect is short and unnecessary stimulation of the let-down reflex can cause uterine cramping and local nasal irritation without additional benefit.
Can I use Oxytocin CD Pharma if I have a cold?
A blocked or very runny nose may reduce the absorption of the spray and make the effect less reliable. Try gently blowing your nose before administration. If you are using a decongestant nasal spray, space the doses apart by at least 30–60 minutes. If nasal symptoms are severe, talk to your prescriber about alternatives during the illness.
How long will I need to use Oxytocin CD Pharma?
Most women use the spray for a few days to a few weeks while the natural let-down reflex is becoming reliable. Long-term continuous use is discouraged. Reassess the need regularly with your lactation consultant, midwife or doctor, and try reducing use as your reflex strengthens.
Is Oxytocin CD Pharma the same as the oxytocin used in hospitals for labour?
The active ingredient is the same hormone, but the dose and route are very different. Hospital oxytocin is given by intravenous infusion at much higher doses under continuous monitoring for labour induction, augmentation, or prevention/treatment of postpartum haemorrhage. Oxytocin CD Pharma is a low-dose nasal spray used outside hospital for milk ejection support after birth.
Does Oxytocin CD Pharma affect my baby?
Oxytocin is a peptide that is broken down rapidly in the infant's stomach and is not absorbed into the baby's circulation in clinically meaningful amounts. International lactation resources consider intranasal oxytocin compatible with continued breastfeeding at therapeutic doses.
References
- European Medicines Agency. Summary of Product Characteristics: Oxytocin intranasal preparations. Amsterdam: EMA; 2024.
- World Health Organization. WHO recommendations on postnatal care of the mother and newborn. Geneva: WHO; 2022.
- Academy of Breastfeeding Medicine. ABM Clinical Protocol #9: Use of galactogogues in initiating or augmenting maternal milk production. Breastfeed Med. 2023;18(1):1–12. doi:10.1089/bfm.2022.29207
- Joint Formulary Committee. British National Formulary (BNF) 87. London: BMJ Group and Pharmaceutical Press; 2024.
- Fewtrell MS, Loh KL, Blake A, Ridout DA, Hawdon J. Randomised, double-blind trial of oxytocin nasal spray in mothers expressing breast milk for preterm infants. Arch Dis Child Fetal Neonatal Ed. 2006;91(3):F169–F174. doi:10.1136/adc.2005.081265
- Ruis H, Rolland R, Doesburg W, Broeders G, Corbey R. Oxytocin enhances onset of lactation among mothers delivering prematurely. BMJ. 1981;283(6287):340–342. doi:10.1136/bmj.283.6287.340
- Uvnäs Moberg K, Ekström-Bergström A, Buckley S, et al. Maternal plasma levels of oxytocin during physiological childbirth — a systematic review with implications for uterine contractions and central actions of oxytocin. BMC Pregnancy Childbirth. 2019;19(1):285. doi:10.1186/s12884-019-2365-9
- US National Library of Medicine. Drugs and Lactation Database (LactMed): Oxytocin. Bethesda: NLM; updated 2024.
- National Institute for Health and Care Excellence. Postnatal care (NG194). London: NICE; 2021.
- World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index: H01BB02 Oxytocin. Oslo: WHOCC; 2025.
Editorial Team
This article was prepared by the iMedic Medical Editorial Team, a multidisciplinary group of licensed specialist physicians in obstetrics, gynaecology, lactation medicine and clinical pharmacology, working to international editorial standards.
Medically reviewed by: iMedic Medical Review Board, in accordance with EMA, WHO and Academy of Breastfeeding Medicine (ABM) guidance.
Last review date: 17 January 2026 | Next scheduled review: January 2027
Conflict of interest: None. iMedic content is independent of pharmaceutical industry funding.
Read more about our editorial standards or meet the medical team.